Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 9

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 9
---
 | the ability of our clinical trials to demonstrate the safety and efficacy of CER-1236 and any other product candidates we may develop, and other positive results; |

| ● | the size and growth potential of the markets for our product candidates, and our ability to serve those markets; |

| ● | our plans relating to the commercialization of CER-1236 and any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales team; |

| ● | the success of competing drugs, therapies or other products that are or may become available; |

| ● | developments relating to our competitors and our industry, including competing product candidates and therapies; |

<div align='center'>iv</div>

| ● | our plans relating to the further development and manufacturing of CER-1236 and any other product candidates we may develop, including additional indications that we may pursue for CER-1236 or other product candidates; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our potential and ability to successfully manufacture and supply CER-1236 and any other product candidates we may develop for clinical trials and for commercial use, if approved; |

| ● | the rate and degree of market acceptance of CER-1236 and any other product candidates we may develop, as well as the pricing and reimbursement of CER-1236 and any other product candidates we may develop, if approved; |

| ● | our expectations regarding our ability to obtain, maintain, protect and enforce intellectual property protection for CER-1236 and for any other product candidate; |

| ● | our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties; |

| ● | our ability to successfully defend litigation that may be instituted against us; |

| ● | our ability to realize the anticipated benefits of any strategic transactions; |

| ● | our ability to attract and retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel and our ability to attract additional collaborators with development, regulatory and commercialization expertise; |

| ● | our ability to maintain proper and effective internal controls; |

| ● | the ability to obtain or maintain the listing of our Common Stock, and our public warrants on the Nasdaq Stock Market (“Nasdaq”); |

| ● | the impact of macroeconomic conditions and geopolitical turmoil on our business and operations, including interest rates,